Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Iowa City, Iowa 52242


Silent myocardial ischemia is known to occur in the general medical intensive care unit population immediately following tracheal extubation. We believe these patients are at risk for primary cardiac events in the 4 hours immediately following extubation. Metoprolol is a selective beta-1 antagonist, with little to no beta-2 activity at low and moderate doses. The cardioprotective effects of beta blockade have been well documented in randomized controlled trials. In patients undergoing extubation, prophylactic use of intravenous metoprolol may reduce post-extubation ischemia events as well as precursors of cardiogenic pulmonary edema (atrial and ventricular wall tension). Our primary hypothesis is that prophylactic metoprolol (titrated to reduce resting heart rate by at least 10%) prior to tracheal extubation will reduce the rate of ischemia as judged by ST segment analysis.


Inclusion Criteria: - Adult medical or cardiac intensive care unit patients on mechanical ventilation who have known coronary artery disease or have at least 2 of the following risk factors for coronary artery disease: - Cigarette smoking - Hypertension (BP 140/90 or antihypertensive medication) - Low HDL-cholesterol (HDL-C) (<40 mg/dL [1.03 mmol/L]) - Family history of premature CHD (in male first degree relatives <55 years, in female first degree relative <65 years) - Age (men 45 years, women 55 years) - Diabetes mellitus - Symptomatic carotid artery disease - Peripheral arterial disease - Abdominal aortic aneurysm Exclusion Criteria: - Arterial hypotension, defined as mean arterial pressure < 60 mmHg or requiring any intravenous vasoactive medication. - The presence of known reactive airway disease. - Resting heart rate of <60 in the period prior to tracheal extubation.. - The presence of decompensated congestive heart failure, defined as requiring continuous infusion of an inotropic agent. - Known hypersensitivity to beta-blockers or any other contraindication to their use. - Subjects younger than 18 years of age. - Inability to obtain consent from the subject or the subjects authorized representative. - Pregnancy - Digoxin therapy - Current therapy with a beta-blocker



Primary Contact:

Principal Investigator
Gregory A Schmidt, MD
University of Iowa

Backup Contact:


Location Contact:

Iowa City, Iowa 52242
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.